NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Tuesday that its second quarter revenues rose 215 percent year over year driven by sales of its rapid pathogen ID molecular diagnostic products.

For the three months ended June 30, the Gaithersburg, Maryland-based firm reported total revenues of $1.2 million compared to $375,146 a year ago. Product sales rose to $1.0 million from $319,171, while lab services revenues rose slightly to $29,674 from $28,195 the year before. Revenues from collaborations rose to $125,000 from $27,780.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.